CorVista wins FDA clearance for AI heart failure assessment add-on
CorVista’s AI-based pulmonary capillary wedge pressure add-on test represents the third FDA clearance for its cardiopulmonary platform.
29 July 2026
29 July 2026
CorVista’s AI-based pulmonary capillary wedge pressure add-on test represents the third FDA clearance for its cardiopulmonary platform.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.